Slide 1: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
May 13, 2026 Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress --Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027— --Company to host confere
Slide 2: Semaglutide Was Selected for the PLATEAU Study
insulin resistance. Semaglutide was selected as the GLP-1 RA for the Phase 2b PLATEAU study to build on Veru’s previous clinical experience using enobosarm in combination with semaglutide in the positive Phase 2 QUALITY clinical study. Further, the clinical data from the Phase 2b PLATEAU clinical tr
Slide 3: Balance Sheet Information
Balance Sheet Information Cash, cash equivalents and restricted cash were $27.6 million as of March 31, 2026 versus $15.8 million as of September 30, 2025 Event Details The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To joi
Slide 4: Forward-Looking Statements (continued)
may be used in combination with enobosarm in future Phase 3 clinical studies and whether the injectable semaglutide used in the PLATEAU Phase 2B study data of enobosarm will support the use of oral semaglutide formulation in combination with oral enobosarm in future Phase 3 clinical studies; The wor
Slide 5: Forward-Looking Statements and Condensed Consolidated Balance Sheets
claims, intellectual property, securities litigation and litigation with the purchaser of the Company’s FC2 business; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired
Slide 6: Condensed Consolidated Statements of Operations
Total stockholders' equity 34,785,621 18,332,670 Total liabilities and stockholders' equity $ 43,082,726 $ 29,835,719 Veru Inc. Condensed Consolidated Statements of Operations (unaudited) Three Months Ended Six Months Ended March 31, March 31, 2026 2025 2026 2025 Operating expenses: Research and dev
Slide 7: Per-Share Results and Statements of Cash Flows
Net income (loss) from discontinued operations per basic and diluted common shares and pre-funded warrants outstanding $ 0.02 $ (0.00 ) $ 0.02 $ (0.49 ) Net loss per basic and diluted common shares and pre- funded warrants outstanding $ (0.12 ) $ (0.54 ) $ (0.37 ) $ (1.15 ) Basic and diluted weighte
Slide 8: Investor and Media Contact
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Source: Veru Inc.